Small molecule inhibitors of the ID2/VHL interaction
This technology describes four chemical compounds that are capable of inhibiting the ID2/VHL interaction for downstream inhibition of tumor growth and angiogenesis.
Unmet Need: Inhibitors of the ID2/VHL interaction in tumors
Tumor hypoxia is linked with poor prognosis, malignancy, and treatment resistance. Hypoxia-inducible factor α (HIFα) plays a role in the transcriptional response to hypoxic stress and is highly expressed in tumor cells. In hypoxic conditions, ID2 interacts with von Hippel-Lindau (VHL) tumor suppressor protein and inhibits proteasomal degradation of HIFα, promoting tumor growth, angiogenesis, and cell proliferation.
The Technology: Small molecule inhibitors of the ID2/VHL interaction
The technology presents four chemical compounds that can inhibit the interaction between ID2 and VHL, leading to the degradation of HIFα. These compounds show a dose-dependent response and can achieve a 50-90% inhibition of ID2/VHL interaction. These compounds could be utilized as potential therapeutic agents for treating various cancers, including gliomas, by blocking tumor growth and angiogenesis.
Applications:
- Drug treatment for gliomas and general solid tumors
- Therapeutic for high-grade terminal gliomas
- Drug treatment for vascular diseases involving deregulated angiogenesis
- Research tool for studies of hypoxia and cancer
Advantages:
- Prevention or slowing of tumor growth and angiogenesis
- Degradation of HIFα could increase tumor cells susceptibility to radiotherapy and chemotherapy
- Alternative treatment option for tumors that are resistant to traditional treatment methods
Lead Inventor:
Related Publications:
Tech Ventures Reference:
IR CU17182, CU16166
Licensing Contact: Kristin Neuman